1. Home
  2. VLN vs IPHA Comparison

VLN vs IPHA Comparison

Compare VLN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valens Semiconductor Ltd.

VLN

Valens Semiconductor Ltd.

HOLD

Current Price

$1.83

Market Cap

188.2M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.77

Market Cap

169.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VLN
IPHA
Founded
2006
1999
Country
Israel
France
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.2M
169.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
VLN
IPHA
Price
$1.83
$1.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$3.00
$5.00
AVG Volume (30 Days)
4.5M
21.6K
Earning Date
02-25-2026
09-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,887,000.00
$14,839,695.00
Revenue This Year
$21.84
$22.29
Revenue Next Year
$11.96
$43.90
P/E Ratio
N/A
N/A
Revenue Growth
7.53
N/A
52 Week Low
$1.37
$1.63
52 Week High
$3.34
$2.63

Technical Indicators

Market Signals
Indicator
VLN
IPHA
Relative Strength Index (RSI) 50.10 48.08
Support Level $1.84 $1.74
Resistance Level $2.15 $1.85
Average True Range (ATR) 0.26 0.08
MACD -0.01 0.01
Stochastic Oscillator 26.25 43.75

Price Performance

Historical Comparison
VLN
IPHA

About VLN Valens Semiconductor Ltd.

Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: